Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Angiotensin I

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    84 result(s) found for: Angiotensin I. Displaying page 2 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2005-003351-12 Sponsor Protocol Number: A6141079 Start Date*: 2005-10-27
    Sponsor Name:Pfizer Ltd
    Full Title: The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure
    Medical condition: Chronic systolic heart failure
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008908 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IE (Completed) SK (Completed) SE (Completed) GB (Completed) ES (Completed) HU (Completed) BE (Completed) PT (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002239-11 Sponsor Protocol Number: MYK-491-003 Start Date*: 2019-04-18
    Sponsor Name:MyoKardia Inc.
    Full Title: Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses...
    Medical condition: Heart Failure with Reduced Ejection Fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002510-38 Sponsor Protocol Number: D3569C00007 Start Date*: 2005-12-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, 52-Week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excreti...
    Medical condition: Male and female patients aged >= 18 and <=70 years with Type 1 or 2 diabetes, moderate proteinuria (baseline urinary protein/creatinine ratio >=500 mg/g and <=5000 mg/g), mild hypercholesterolaemia...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001176-12 Sponsor Protocol Number: CSPP100A2325 Start Date*: 2006-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study to compare the effects of multiple dose administration of aliskiren and irbesartan on biomarkers of inflammation and cardiovascular ri...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010207-83 Sponsor Protocol Number: n3PUFA2009 Start Date*: 2009-06-08
    Sponsor Name:Lehrstuhl für Klinisch-Experimentelle Medizin, Universitaet des Saarlandes
    Full Title: Effect of Omega-3 Fatty Acids (n3-PUFA, Zodin®) on Post-Prandial Triglyceride Tolerance
    Medical condition: The proposed study investigates post-prandial hypertriglyceridemia, i.e. patients with a pathological increase in serum-triglyceride levels after intake of a fatty meal.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006867-22 Sponsor Protocol Number: FNMPK012007 Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Motol
    Full Title: Treatment of proteinuria with angiotensin-converting enzyme inhibitor in children after renal transplantation
    Medical condition: proteinuria and hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037032 Proteinuria LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000161-40 Sponsor Protocol Number: AdrenalClock Start Date*: 2022-07-18
    Sponsor Name:Medical University of Vienna, Division of Endocrinology
    Full Title: Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion
    Medical condition: Autonomous cortisol secretion in patients with adrenal adenoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002737-39 Sponsor Protocol Number: Start Date*: 2005-06-14
    Sponsor Name:National Headache Institute
    Full Title: Prophylactic treatment of episodic cluster headache with an angiotensin II receptor blocker (candesartan cilexetil); a randomized, placebo controlled parallel study.
    Medical condition: Episodic cluster headache
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001670-28 Sponsor Protocol Number: BER-1272-0058-I Start Date*: 2013-03-18
    Sponsor Name:Medizinische Fakultät der Technischen Universität München
    Full Title: Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema BERINERT Randomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced Angioedema
    Medical condition: Angiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004870 10002425 Angioedemas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001287-34 Sponsor Protocol Number: BAY1067197/16718 Start Date*: 2013-11-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: A single blind, placebo controlled pilot study to explore the safety and tolerability of a single oral dose of 30 mg BAY 1067197 in patients with chronic heart failure on the background of preexist...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10019279 Heart failure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005724-10 Sponsor Protocol Number: SPIHF-201 Start Date*: 2016-06-07
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart...
    Medical condition: Stable Heart Failure with Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006579-41 Sponsor Protocol Number: ANG3070-CKD-201 Start Date*: 2022-03-07
    Sponsor Name:Angion Biomedica Corp.
    Full Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria
    Medical condition: Primary glomerular disease and persistent proteinuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10037032 Proteinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002516-33 Sponsor Protocol Number: NCT01420393 Start Date*: 2015-09-03
    Sponsor Name:University of Ottawa Heart Institute
    Full Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation
    Medical condition: The study is comparing two accepted treatment methods (rhythm control-Catheter ablation with or without anti-arrhythmic drug control of maintaining sinus rhythm versus rate controls with medical th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001039-72 Sponsor Protocol Number: RP06 Start Date*: 2008-03-06
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust, jointly with University of Cambridge
    Full Title: Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial
    Medical condition: Type 1 diabetes in adolescents
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012609 Diabetes mellitus juvenile onset LLT
    14.0 10027433 - Metabolism and nutrition disorders 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001187-33 Sponsor Protocol Number: APD811-301 Start Date*: 2019-02-12
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003297-53 Sponsor Protocol Number: 18748 Start Date*: 2020-10-15
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of individually titrated oral doses of runcaciguat in subjects with clinical diagnosis of chroni...
    Medical condition: Treatment of cardiovascular and renal disease in patients with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) IT (Completed) FI (Completed) SE (Completed) ES (Completed) PL (Completed) AT (Completed) BE (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001364-29 Sponsor Protocol Number: AdiQure/COVID-19 Start Date*: 2020-04-20
    Sponsor Name:Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud
    Full Title: Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia
    Medical condition: Severe COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004225-10 Sponsor Protocol Number: 3001081 Start Date*: 2005-03-07
    Sponsor Name:Orion Pharma
    Full Title: Effects of peroral levosimendan in the prevention of further hospitalisations in patients with chronic heart failure. A randomised, double-blind, placebo-controlled, multi-centre, parallel-group study
    Medical condition: Cardiac Failure
    Disease: Version SOC Term Classification Code Term Level
    7.1 10007554 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002570-27 Sponsor Protocol Number: 69TER/2020 Start Date*: 2021-05-27
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: A Randomized Clinical Trial of Nafamostat: A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor for the Treatment of Covid-19
    Medical condition: Covid-19 (Coronavirus disease 2019) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005054-19 Sponsor Protocol Number: MOR202C206 Start Date*: 2021-07-28
    Sponsor Name:Human Immunology Biosciences, Inc
    Full Title: A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ
    Medical condition: IgA Nephropathy (IgAN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 19:22:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA